Endocrine Abstracts

Epidemiological and preclinical studies propose that metformin, a first-line drug for type- 2 diabetes, exerts direct antitumoral activity. Although several clinical trials are currently ongoing, the molecular mechanisms of this effect are unknown. The AMP-activated kinase-dependent pathway, and the down-stream effectors (e.g. mTOR) are considered the main effectors. Several studies reported the involvement of, in metformin metabolic activity. Nevertheless, contrasting evidenc...